Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is a paper indexed in PICO Portal from OpenAlex.

How many citations does Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study have?

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has 794 citations in the OpenAlex counts PICO Portal stores.

When was Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study published?

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has 2018 year in the PICO Portal index.

What is the open-access status of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has closed oa status in the PICO Portal index.

What is the DOI of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?

The DOI for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.

What is the PMID of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?

The PMID for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.

What is the OpenAlex record for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?

The OpenAlex for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.